Health benefits of combined oral contraceptives – a narrative review

References

• Haberlandt E. Ludwig haberlandt–a pioneer in hormonal contraception. Wien Klin Wochenschr. 2009;121(23–24):746–749. doi: 10.1007/s00508-009-1280-x.
   PubMed Web of Science ®Google Scholar
• Djerassi C. Ludwig haberlandt–”grandfather of the pill”. Wien Klin Wochenschr. 2009;121(23-24):727–728. doi: 10.1007/s00508-009-1271-y.
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343(oct25 4):d6423–d6423. doi: 10.1136/bmj.d6423.
   PubMedGoogle Scholar
• Tricotel A, Raguideau F, Collin C, et al. Estimate of venous thromboembolism and related-deaths attributable to the use of combined oral contraceptives in France. PLoS One. 2014;9(4):e93792. doi: 10.1371/journal.pone.0093792.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2015;350(13):h2135–h2135. doi: 10.1136/bmj.h2135.
   PubMedGoogle Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi: 10.1136/bmj.k4810.
   PubMed Web of Science ®Google Scholar
• Lete I, Chabbert-Buffet N, Jamin C, et al. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review. Eur J Contracept Reprod Health Care. 2015;20(5):329–343. doi: 10.3109/13625187.2015.1050091.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020;102(6):396–402. doi: 10.1016/j.contraception.2020.08.015.
   PubMed Web of Science ®Google Scholar
• Reed S, Koro C, DiBello J, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17beta-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care. 2021;26(6):439–446. doi: 10.1080/13625187.2021.1987410.
   PubMed Web of Science ®Google Scholar
• Grossman BN. Managing adverse effects of hormonal contraceptives. Am Fam Physician. 2010;82(12):1499–1506.
   PubMed Web of Science ®Google Scholar
• Cooper DB, Patel P, Mahdy H. Oral contraceptive pills. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
   Google Scholar
• Speroff LaF M. The clinical gynecologic endocrinology and infertility. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.
   Google Scholar
• Bui HN, Sluss PM, Blincko S, et al. Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay. Steroids. 2013;78(1):96–101. doi: 10.1016/j.steroids.2012.10.010.
   PubMed Web of Science ®Google Scholar
• van Lunsen RHW, Zimmerman Y, Coelingh Bennink HJT, et al. Maintaining physiologic testosterone levels during combined oral contraceptives by adding dehydroepiandrosterone: II. Effects on sexual function. A phase II randomized, double-blind, placebo-controlled study. Contraception. 2018;98(1):56–62. doi: 10.1016/j.contraception.2018.02.014.
   PubMed Web of Science ®Google Scholar
• Zimmerman Y, Foidart JM, Pintiaux A, et al. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects. Contraception. 2015;91(2):134–142. doi: 10.1016/j.contraception.2014.11.008.
   PubMed Web of Science ®Google Scholar
• Ory HW, Rosenfield A, Landman LC. The pill at 20: an assessment. Fam Plann Perspect. 1980;12(6):278–283. doi: 10.2307/2134658.
   PubMedGoogle Scholar
• Peterson HB, Lee NC. The health effects of oral contraceptives: misperceptions, controversies, and continuing good news. Clin Obstet Gynecol. 1989;32(2):339–355. doi: 10.1097/00003081-198906000-00019.
   PubMed Web of Science ®Google Scholar
• Grimes DA. The safety of oral contraceptives: epidemiologic insights from the first 30 years. Am J Obstet Gynecol. 1992;166(6):1950–1954. doi: 10.1016/0002-9378(92)91394-p.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000;27(4):705–721. doi: 10.1016/s0889-8545(05)70169-8.
   PubMed Web of Science ®Google Scholar
• Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol. 2001;44(1):62–72. doi: 10.1097/00003081-200103000-00010.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM. Noncontraceptive health benefits of oral contraceptives. Rev Endocr Metab Disord. 2002;3(3):277–283. doi: 10.1023/a:1020084728544.
   PubMedGoogle Scholar
• ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update. 2005;11(5):513–525.
   PubMed Web of Science ®Google Scholar
• Huber JC, Bentz EK, Ott J, et al. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother. 2008;9(13):2317–2325. doi: 10.1517/14656566.9.13.2317.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;115(1):206–218.
   PubMedGoogle Scholar
• Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41–47. doi: 10.5812/ijem.4158.
   PubMedGoogle Scholar
• Nappi RE, Serrani M, Jensen JT. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. Int J Womens Health. 2014;6:711–718. doi: 10.2147/IJWH.S65481.
   PubMedGoogle Scholar
• Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update. 2015;21(5):640–651. doi: 10.1093/humupd/dmv023.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Bruni V, Di Carlo C, et al. How often is oral contraception used for contraception? The need of benefit’s formalisation. Eur J Contracept Reprod Health Care. 2023;28(2):81–82. doi: 10.1080/13625187.2023.2170711.
   PubMed Web of Science ®Google Scholar
• Palacios S, Regidor PA, Colli E, et al. Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature. Eur J Contracept Reprod Health Care. 2020;25(3):221–227. doi: 10.1080/13625187.2020.1743828.
   PubMed Web of Science ®Google Scholar
• Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. doi: 10.1002/ijgo.12666.
   PubMed Web of Science ®Google Scholar
• Fraser IS, Langham S, Uhl-Hochgraeber K. Health-related quality of life and economic burden of abnormal uterine bleeding. Expert Rev Obstet Gynecol. 2009;4(2):179–189. doi: 10.1586/17474108.4.2.179.
   Google Scholar
• Lethaby A, Wise MR, Weterings MA, et al. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2: CD000154.
   PubMedGoogle Scholar
• Iron deficiency--United States, 1999–2000. MMWR Morb Mortal Wkly Rep. 2002;51(40):897–899.
   Google Scholar
• Bellizzi S, Ali MM. Effect of oral contraception on anemia in 12 low- and Middle-income countries. Contraception. 2018;97(3):236–242. doi: 10.1016/j.contraception.2017.11.001.
   PubMed Web of Science ®Google Scholar
• Gellert SHA. Iron status in relation to oral contraceptive use in women of reproductive age. Austin J Women’s Health. 2017;4(1):1025.
   Google Scholar
• Casabellata G, Di Santolo M, Banfi G, et al. Evaluation of iron deficiency in young women in relation to oral contraceptive use. Contraception. 2007;76(3):200–207. doi: 10.1016/j.contraception.2007.04.016.
   PubMed Web of Science ®Google Scholar
• Gray RH. Toxic shock syndrome and oral contraception. Am J Obstet Gynecol. 1987; Apr156(4):1038. doi: 10.1016/0002-9378(87)90382-6.
   PubMed Web of Science ®Google Scholar
• Ross A, Shoff HW. Toxic shock syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
   Google Scholar
• Latthe P, Latthe M, Say L, et al. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health. 2006;6(1):177. doi: 10.1186/1471-2458-6-177.
   PubMed Web of Science ®Google Scholar
• Wong CL, Farquhar C, Roberts H, et al. Oral contraceptive pill as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev. 2009;15(2):CD002120.
   Google Scholar
• Latthe PM, Champaneria R, Khan KS. Dysmenorrhoea. BMJ Clin Evid. 2011;2011:02–813.
   Google Scholar
• Lindh I, Ellström AA, Milsom I. The effect of combined oral contraceptives and age on dysmenorrhoea: an epidemiological study. Hum Reprod. 2012;27(3):676–682. doi: 10.1093/humrep/der417.
   PubMed Web of Science ®Google Scholar
• Wilson CA, Keye WR.Jr. A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment. J Adolesc Health Care. 1989;10(4):317–322. doi: 10.1016/0197-0070(89)90065-x.
   PubMedGoogle Scholar
• Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception. 1990;42(5):497–506. doi: 10.1016/0010-7824(90)90078-a.
   PubMed Web of Science ®Google Scholar
• Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol. 1990;97(7):588–594. doi: 10.1111/j.1471-0528.1990.tb02545.x.
   PubMedGoogle Scholar
• Edelman A, Micks E, Gallo MF. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014;2014(7):Cd004695.
   PubMedGoogle Scholar
• Momoeda M, Kondo M, Elliesen J, et al. Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. Int J Womens Health. 2017;9:295–305. doi: 10.2147/IJWH.S134576.
   PubMed Web of Science ®Google Scholar
• Grandi G, Barra F, Ferrero S, et al. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019;24(1):61–70. doi: 10.1080/13625187.2018.1550576.
   PubMed Web of Science ®Google Scholar
• Vetvik KG, Macgregor EA, Lundqvist C, et al. Prevalence of menstrual migraine: a population-based study. Cephalalgia. 2014;34(4):280–288. doi: 10.1177/0333102413507637.
   PubMed Web of Science ®Google Scholar
• Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol. 2014;27(3):315–324. doi: 10.1097/WCO.0000000000000091.
   PubMed Web of Science ®Google Scholar
• Calhoun AH, Batur P. Combined hormonal contraceptives and migraine: an update on the evidence. Cleve Clin J Med. 2017;84(8):631–638. doi: 10.3949/ccjm.84a.16033.
   PubMed Web of Science ®Google Scholar
• Nierenburg HDC, Ailani J, Malloy M, et al. Systematic review of preventive and acute treatment of menstrual migraine. Headache. 2015;55(8):1052–1071. doi: 10.1111/head.12640.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Caveng N, Speiermann G, et al. Migraine start, course and features over the cycle of combined hormonal contraceptive users with menstrual migraine - temporal relation to bleeding and hormone withdrawal: a prospective diary-based study. J Headache Pain. 2020;21(1):81. doi: 10.1186/s10194-020-01150-1.
   PubMed Web of Science ®Google Scholar
• Champaloux SW, Tepper NK, Monsour M, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216(5):489.e1–489.e7. doi: 10.1016/j.ajog.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Kwan I, Onwude JL. Premenstrual syndrome. BMJ Clin Evid. 2015;2015:0806.
   PubMedGoogle Scholar
• Lete I, Lapuente O. Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review. Open Access J Contracept. 2016;7:117–125. doi: 10.2147/OAJC.S97013.
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Korotkaya Y, Taylor KC. Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives. Open Access J Contracept. 2019;10:27–39. doi: 10.2147/OAJC.S183193.
   PubMed Web of Science ®Google Scholar
• de Wit AE, de Vries YA, de Boer MK, et al. Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials. Am J Obstet Gynecol. 2021;225(6):624–633. doi: 10.1016/j.ajog.2021.06.090.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2(2):CD006586. doi: 10.1002/14651858.CD006586.pub4.
   Google Scholar
• Ma S, Song SJ. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2023;6(6):CD006586.
   PubMedGoogle Scholar
• Mobeen S, Apostol R. Ovarian cyst. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
   Google Scholar
• Functional ovarian cysts and oral contraceptives: negative association confirmed surgically. JAMA. 1974;228(1):68–69.
   PubMed Web of Science ®Google Scholar
• Lanes SF, Birmann B, Walker AM, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol. 1992;166(3):956–961. doi: 10.1016/0002-9378(92)91371-g.
   PubMed Web of Science ®Google Scholar
• Grimes DA, Jones LB, Lopez LM, et al. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. 2011;7(9):CD006134.
   Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47.
   PubMed Web of Science ®Google Scholar
• Deswal R, Narwal V, Dang A, et al. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261–271. doi: 10.4103/jhrs.JHRS_95_18.
   PubMedGoogle Scholar
• Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855. doi: 10.1093/humrep/dew218.
   PubMed Web of Science ®Google Scholar
• Teede H, Tassone EC, Piltonen T, et al. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses. Clin Endocrinol (Oxf). 2019;91(4):479–489. doi: 10.1111/cen.14013.
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592. doi: 10.1210/jc.2013-2350.
   PubMed Web of Science ®Google Scholar
• Bianchi VE, Bresciani E, Meanti R, et al. The role of androgens in women’s health and wellbeing. Pharmacol Res. 2021;171:105758. doi: 10.1016/j.phrs.2021.105758.
   PubMed Web of Science ®Google Scholar
• Ramos-e-Silva M, Ramos-e-Silva S, Carneiro S. Acne in women. Br J Dermatol. 2015;172:20–26. doi: 10.1111/bjd.13638.
   PubMed Web of Science ®Google Scholar
• Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;11(7):CD004425.
   Google Scholar
• Abitbol J, Abitbol P, Abitbol B. Sex hormones and the female voice. J Voice. 1999;13(3):424–446. doi: 10.1016/s0892-1997(99)80048-4.
   PubMed Web of Science ®Google Scholar
• Rodney JP, Sataloff RT. The effects of hormonal contraception on the voice: history of its evolution in the literature. J Voice. 2016;30(6):726–730. doi: 10.1016/j.jvoice.2015.08.014.
   PubMed Web of Science ®Google Scholar
• Kopp-Kallner H, Linder M, Cesta CE, et al. Method of hormonal contraception and protective effects against ectopic pregnancy. Obstet Gynecol. 2022;139(5):764–770. doi: 10.1097/AOG.0000000000004726.
   PubMed Web of Science ®Google Scholar
• Casper RF, Dodin S, Reid RL. The effect of 20 μg ethinyl estradiol/1 mg norethindrone acetate (MinestrinTM), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause. 1997;4(3):139–147.
   Web of Science ®Google Scholar
• Porcile A, Gallardo E, Onetto P, et al. Very low estrogen-desogestrel contraceptive in perimenopausal hormonal replacement. Maturitas. 1994;18(2):93–103. doi: 10.1016/0378-5122(94)90047-7.
   PubMed Web of Science ®Google Scholar
• Blümel JE, Castelo-Branco C, Binfa L, et al. A scheme of combined oral contraceptives for women more than 40 years old. Menopause. 2001;8(4):286–289. doi: 10.1097/00042192-200107000-00011.
   PubMed Web of Science ®Google Scholar
• Kailas NA, Sifakis S, Koumantakis E. Contraception during perimenopause. Eur J Contracept Reprod Health Care. 2005;10(1):19–25. doi: 10.1080/13625180400020861.
   PubMed Web of Science ®Google Scholar
• Cho MK. Use of combined oral contraceptives in perimenopausal women. Chonnam Med J. 2018;54(3):153–158. doi: 10.4068/cmj.2018.54.3.153.
   PubMedGoogle Scholar
• Kaunitz AM. Oral contraceptive use in perimenopause. Am J Obstet Gynecol. 2001;185(2 Suppl):S32–S7. doi: 10.1067/mob.2001.116525.
   PubMed Web of Science ®Google Scholar
• Chen EC, Brzyski RG. Exercise and reproductive dysfunction. Fertil Steril. 1999;71(1):1–6. doi: 10.1016/s0015-0282(98)00392-6.
   PubMed Web of Science ®Google Scholar
• Huhmann K. Menses requires energy: a review of how disordered eating, excessive exercise, and high stress lead to menstrual irregularities. Clin Ther. 2020;42(3):401–407. doi: 10.1016/j.clinthera.2020.01.016.
   PubMed Web of Science ®Google Scholar
• Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382(13):1244–1256. doi: 10.1056/NEJMra1810764.
   PubMed Web of Science ®Google Scholar
• Gunther R, Walker C. Adenomyosis. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
   Google Scholar
• Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019;220(4):354.e1–354.e12. doi: 10.1016/j.ajog.2018.12.039.
   PubMed Web of Science ®Google Scholar
• Brown J, Crawford TJ, Datta S, et al. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2018;5(5):Cd001019.
   PubMedGoogle Scholar
• Cope AG, Ainsworth AJ, Stewart EA. Current and future medical therapies for adenomyosis. Semin Reprod Med. 2020;38(2):151–156. doi: 10.1055/s-0040-1719016.
   PubMedGoogle Scholar
• Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405. doi: 10.1016/j.fertnstert.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571–588. doi: 10.1016/j.bpobgyn.2008.04.002.
   PubMed Web of Science ®Google Scholar
• Moroni RM, Martins WP, Dias SV, et al. Combined oral contraceptive for treatment of women with uterine fibroids and abnormal uterine bleeding: a systematic review. Gynecol Obstet Invest. 2015;79(3):145–152. doi: 10.1159/000369390.
   PubMed Web of Science ®Google Scholar
• Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol. 1982;144(6):630–635. doi: 10.1016/0002-9378(82)90430-6.
   PubMed Web of Science ®Google Scholar
• Panser LA, Phipps WR. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception. 1991;43(1):91–99. doi: 10.1016/0010-7824(91)90130-8.
   PubMed Web of Science ®Google Scholar
• Vessey M, Yeates D. Oral contraceptives and benign breast disease: an update of findings in a large cohort study. Contraception. 2007;76(6):418–424. doi: 10.1016/j.contraception.2007.08.011.
   PubMed Web of Science ®Google Scholar
• Charreau I, Plu-Bureau G, Bachelot A, et al. Oral contraceptive use and risk of benign breast disease in a French case-control study of young women. Eur J Cancer Prev. 1993;2(2):147–154. doi: 10.1097/00008469-199303000-00007.
   PubMedGoogle Scholar
• Brinton LA, Vessey MP, Flavel R, et al. Risk factors for benign breast disease. Am J Epidemiol. 1981;113(3):203–214. doi: 10.1093/oxfordjournals.aje.a113089.
   PubMed Web of Science ®Google Scholar
• Southmayd EA, De Souza MJ. A summary of the influence of exogenous estrogen administration across the lifespan on the GH/IGF-1 axis and implications for bone health. Growth Horm IGF Res. 2017;32:2–13. doi: 10.1016/j.ghir.2016.09.001.
   PubMed Web of Science ®Google Scholar
• Bachrach LK. Hormonal contraception and bone health in adolescents. Front Endocrinol (Lausanne). 2020;11:603. doi: 10.3389/fendo.2020.00603.
   PubMed Web of Science ®Google Scholar
• Brajic TS, Berger C, Schlammerl K, et al. Combined hormonal contraceptives use and bone mineral density changes in adolescent and young women in a prospective population-based Canada-wide observational study. J Musculoskelet Neuronal Interact. 2018;18(2):227–236.
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Cappagli B, Lazzarini V, et al. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas. 2006;54(2):176–180. doi: 10.1016/j.maturitas.2005.10.007.
   PubMed Web of Science ®Google Scholar
• Shargil AA. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int J Fertil. 1985;30(1):15, 18–28.
   PubMedGoogle Scholar
• Kleerekoper M, Brienza RS, Schultz LR, et al. Oral contraceptive use may protect against low bone mass. Arch Intern Med. 1991;151(10):1971–1976. doi: 10.1001/archinte.1991.00400100053009.
   PubMedGoogle Scholar
• Michaëlsson K, Baron JA, Farahmand BY, et al. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet. 1999;353(9163):1481–1484. doi: 10.1016/S0140-6736(98)09044-8.
   PubMed Web of Science ®Google Scholar
• DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol. 1996;174(1 Pt 1):15–20. doi: 10.1016/s0002-9378(96)70366-6.
   PubMed Web of Science ®Google Scholar
• Nappi C, Bifulco G, Tommaselli GA, et al. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012;86(6):606–621. doi: 10.1016/j.contraception.2012.04.009.
   PubMed Web of Science ®Google Scholar
• Kontzias A. Rheumatoid arthritis (RA). 2020. (Merk Manual, professional Version).
   Google Scholar
• Lopane CM, Comstock B, Nagel AK, et al. Combined oral contraceptive use in rheumatoid arthritis for the purpose of pregnancy prevention and additional benefits: a narrative review. J Obstet Gynaecol Res. 2022;48(2):306–312. doi: 10.1111/jog.15097.
   PubMed Web of Science ®Google Scholar
• Drossaers-Bakker KW, Zwinderman AH, van Zeben D, et al. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis. 2002;61(5):405–408. doi: 10.1136/ard.61.5.405.
   PubMed Web of Science ®Google Scholar
• Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol. 1990;43(11):1221–1230. doi: 10.1016/0895-4356(90)90023-i.
   PubMed Web of Science ®Google Scholar
• Orellana C, Saevarsdottir S, Klareskog L, et al. Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2017;76(11):1845–1852. doi: 10.1136/annrheumdis-2017-211620.
   PubMed Web of Science ®Google Scholar
• Albrecht K, Callhoff J, Buttgereit F, et al. Association between the use of oral contraceptives and Patient-Reported outcomes in an early arthritis cohort. Arthritis Care Res (Hoboken). 2016;68(3):400–405. doi: 10.1002/acr.22667.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Brizzolara R, Atzeni F, et al. The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann N Y Acad Sci. 2010;1193(1):36–42. doi: 10.1111/j.1749-6632.2009.05383.x.
   PubMedGoogle Scholar
• Farr SL, Folger SG, Paulen ME, et al. Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review. Contraception. 2010;82(1):64–71. doi: 10.1016/j.contraception.2010.02.003.
   PubMed Web of Science ®Google Scholar
• Brennan P, Bankhead C, Silman A, et al. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum. 1997;26(6):817–823. doi: 10.1016/s0049-0172(97)80025-x.
   PubMed Web of Science ®Google Scholar
• Hazes JM, Dijkmans BC, Vandenbroucke JP, et al. Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis Rheum. 1990;33(2):173–179. doi: 10.1002/art.1780330204.
   PubMedGoogle Scholar
• Amini L, Kalhor M, Haghighi A, et al. Effect of oral contraceptive pills on rheumatoid arthritis disease activity in women: a randomized clinical trial. Med J Islam Republic of Iran. 2018;32:61.
   PubMedGoogle Scholar
• Holmqvist P, Hammar M, Landtblom AM, et al. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril. 2010;94(7):2835–2837. doi: 10.1016/j.fertnstert.2010.06.045.
   PubMed Web of Science ®Google Scholar
• Otero-Romero S, Carbonell-Mirabent P, Midaglia L, et al. Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Mult Scler. 2022;28(6):950–957. doi: 10.1177/13524585211053001.
   PubMed Web of Science ®Google Scholar
• Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932–936. doi: 10.1016/S1474-4422(06)70581-6.
   PubMed Web of Science ®Google Scholar
• D’Hooghe MB, Haentjens P, Nagels G, et al. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol. 2012;259(5):855–861. doi: 10.1007/s00415-011-6267-7.
   PubMed Web of Science ®Google Scholar
• Alonso A, Jick SS, Olek MJ, et al. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol. 2005;62(9):1362–1365. doi: 10.1001/archneur.62.9.1362.
   PubMedGoogle Scholar
• Bernardi S, Grasso MG, Bertollini R, et al. The influence of pregnancy on relapses in multiple sclerosis: a cohort study. Acta Neurol Scand. 1991;84(5):403–406. doi: 10.1111/j.1600-0404.1991.tb04977.x.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med. 1998;339(5):285–291. doi: 10.1056/NEJM199807303390501.
   PubMed Web of Science ®Google Scholar
• Damek DM, Shuster EA. Pregnancy and multiple sclerosis. Mayo Clin Proc. 1997;72(10):977–989. doi: 10.1016/S0025-6196(11)63371-5.
   PubMed Web of Science ®Google Scholar
• Houtchens MK, Zapata LB, Curtis KM, et al. Contraception for women with multiple sclerosis: guidance for healthcare providers. Mult Scler. 2017;23(6):757–764. doi: 10.1177/1352458517701314.
   PubMed Web of Science ®Google Scholar
• Hernán MA, Hohol MJ, Olek MJ, et al. Oral contraceptives and the incidence of multiple sclerosis. Neurology. 2000;55(6):848–854. doi: 10.1212/wnl.55.6.848.
   PubMed Web of Science ®Google Scholar
• Hellwig K, Chen LH, Stancyzk FZ, et al. Oral contraceptives and multiple sclerosis/clinically isolated syndrome susceptibility. PLoS One. 2016;11(3):e0149094. doi: 10.1371/journal.pone.0149094.
   PubMed Web of Science ®Google Scholar
• Sena A, Couderc R, Vasconcelos JC, et al. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci. 2012;317(1–2):47–51. doi: 10.1016/j.jns.2012.02.033.
   PubMed Web of Science ®Google Scholar
• Gava G, Bartolomei I, Costantino A, et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril. 2014;102(1):116–122. doi: 10.1016/j.fertnstert.2014.03.054.
   PubMed Web of Science ®Google Scholar
• Mims JW. editor Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5 Suppl 1(S1):S2–S6. doi: 10.1002/alr.21609.
   PubMedGoogle Scholar
• Becklake MR, Kauffmann F. Gender differences in airway behaviour over the human life span. Thorax. 1999;54(12):1119–1138. doi: 10.1136/thx.54.12.1119.
   PubMed Web of Science ®Google Scholar
• Salam MT, Wenten M, Gilliland FD. Endogenous and exogenous sex steroid hormones and asthma and wheeze in young women. J Allergy Clin Immunol. 2006;117(5):1001–1007. doi: 10.1016/j.jaci.2006.02.004.
   PubMed Web of Science ®Google Scholar
• Baibergenova A, Thabane L, Akhtar-Danesh N, et al. Sex differences in hospital admissions from emergency departments in asthmatic adults: a population-based study. Ann Allergy Asthma Immunol. 2006;96(5):666–672. doi: 10.1016/S1081-1206(10)61063-0.
   PubMed Web of Science ®Google Scholar
• Kynyk JA, Mastronarde JG, McCallister JW. Asthma, the sex difference. Curr Opin Pulm Med. 2011;17(1):6–11. doi: 10.1097/MCP.0b013e3283410038.
   PubMed Web of Science ®Google Scholar
• Prescott E, Lange P, Vestbo J. Effect of gender on hospital admissions for asthma and prevalence of self-reported asthma: a prospective study based on a sample of the general population. Copenhagen city heart study group. Thorax. 1997;52(3):287–289. doi: 10.1136/thx.52.3.287.
   PubMed Web of Science ®Google Scholar
• Haggerty CL, Ness RB, Kelsey S, et al. The impact of estrogen and progesterone on asthma. Ann Allergy Asthma Immunol. 2003;90(3):284–291. doi: 10.1016/S1081-1206(10)61794-2.
   PubMed Web of Science ®Google Scholar
• Forbes L. Do exogenous oestrogens and progesterone influence asthma? Thorax. 1999;54(3):265–267. doi: 10.1136/thx.54.3.265.
   PubMed Web of Science ®Google Scholar
• Nwaru BI, Sheikh A. Hormonal contraceptives and asthma in women of reproductive age: analysis of data from serial national Scottish Health Surveys. J R Soc Med. 2015;108(9):358–371. doi: 10.1177/0141076815588320.
   PubMed Web of Science ®Google Scholar
• Nwaru BI, Tibble H, Shah SA, et al. Hormonal contraception and the risk of severe asthma exacerbation: 17-year population-based cohort study. Thorax. 2021;76(2):109–115. doi: 10.1136/thoraxjnl-2020-215540.
   PubMed Web of Science ®Google Scholar
• Forbes L, Jarvis D, Burney P. Do hormonal contraceptives influence asthma severity? Eur Respir J. 1999;14(5):1028–1033. doi: 10.1183/09031936.99.14510289.
   PubMed Web of Science ®Google Scholar
• Jenkins MA, Dharmage SC, Flander LB, et al. Parity and decreased use of oral contraceptives as predictors of asthma in young women. Clin Exp Allergy. 2006;36(5):609–613. doi: 10.1111/j.1365-2222.2006.02475.x.
   PubMed Web of Science ®Google Scholar
• Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol. 2017;176(4):527–538. doi: 10.1111/bjh.14459.
   PubMed Web of Science ®Google Scholar
• Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377(21):2101–2872. doi: 10.1056/NEJMra1608634.
   PubMedGoogle Scholar
• Wheeler J, Valente JR, Mody MD, et al. Severe acute hyponatremia as an initial presentation of acute intermittent porphyria triggered by a subdermal etonogestrel implant. J Nephrol Renal Ther. 2016;2(1):1–4. doi: 10.24966/NRT-7313/100006.
   Google Scholar
• Andersson C, Innala E, Bäckström T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in Northern Sweden. J Intern Med. 2003;254(2):176–183. doi: 10.1046/j.1365-2796.2003.01172.x.
   PubMed Web of Science ®Google Scholar
• Gross U, Honcamp M, Daume E, et al. Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Horm Metab Res. 1995;27(8):379–383. doi: 10.1055/s-2007-979983.
   PubMed Web of Science ®Google Scholar
• Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(4 Suppl):S5–S22. doi: 10.1016/j.ajog.2004.01.061.
   PubMed Web of Science ®Google Scholar
• Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol. 2015;25(3):193–200. doi: 10.1016/j.annepidem.2014.11.004.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, de Gonzalez AB. The pill’s gestation: from birth control to cancer prevention. Lancet Oncol. 2015;16(9):1004–1006. doi: 10.1016/S1470-2045(15)00211-9.
   PubMed Web of Science ®Google Scholar
• Collaborative group on hormonal factors in breast cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713–1727.
   PubMed Web of Science ®Google Scholar
• Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22(11):1931–1943. doi: 10.1158/1055-9965.EPI-13-0298.
   PubMed Web of Science ®Google Scholar
• FDA. Label Twirla. Revised 2/2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204017s000lbl.pdf
   Google Scholar
• Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018;4(4):516–521. doi: 10.1001/jamaoncol.2017.4942.
   PubMed Web of Science ®Google Scholar
• Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the royal college of general practitioners’ oral contraception study. Am J Obstet Gynecol. 2017;216(6):580 e1–580 e9.
   PubMed Web of Science ®Google Scholar
• Collaborative group on epidemiological studies on endometrial C. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16(9):1061–1070.
   PubMed Web of Science ®Google Scholar
• Burchardt NA, Shafrir AL, Kaaks R, et al. Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947-1964: the nurses’ health study II, a prospective cohort study. Eur J Epidemiol. 2021;36(8):827–839. doi: 10.1007/s10654-020-00705-5.
   PubMed Web of Science ®Google Scholar
• Iversen L, Fielding S, Lidegaard O, et al. Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of Danish women. Contraception. 2020;102(3):152–158. doi: 10.1016/j.contraception.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol. 1992;80(4):708–714.
   PubMed Web of Science ®Google Scholar
• Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–4198. doi: 10.1200/JCO.2013.48.9021.
   PubMed Web of Science ®Google Scholar
• Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275–2284. doi: 10.1016/j.ejca.2010.04.018.
   PubMed Web of Science ®Google Scholar
• Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014; Jun106(6):dju091. doi: 10.1093/jnci/dju091.
   PubMedGoogle Scholar
• Committee for Medical Products for Human Use (CPMP). Guideline on clinical investigation of steroid contraceptives in women. 2005 [cited 2023 Aug 1]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-steroid-contraceptives-women_en.pdf.
   Google Scholar
• Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(1):139–147. doi: 10.1097/AOG.0b013e318291c235.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888–2898. doi: 10.1200/JCO.2016.66.8178.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–314.
   PubMed Web of Science ®Google Scholar
• Luan NN, Wu L, Gong TT, et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies. Cancer Causes Control. 2015;26(1):65–78. doi: 10.1007/s10552-014-0483-2.
   PubMed Web of Science ®Google Scholar
• Murphy N, Xu L, Zervoudakis A, et al. Reproductive and menstrual factors and colorectal cancer incidence in the women’s health initiative observational study. Br J Cancer. 2017;116(1):117–125. doi: 10.1038/bjc.2016.345.
   PubMed Web of Science ®Google Scholar